Table 5:

Association of anti-retinal autoantibodies with 9 most common cancers in cancer-associated retinopathy (CAR)

Cancer	Incidence of cancer	Most frequent AAbs against retinal markers	Time from AAbs detection to cancer diagnosis	Major symptoms and findings
Breast	22% (96/441)	Enolase, GAPDH, CAII, recoverin	Mostly after or at the time of diagnosis	Photopsia/photophobia, VA loss, ffERG dysfunction, pigmentary changes
Gynecological (ovarian, endometrial, uterine, cervical)	7% (33/441)	GAPDH, aldolase, enolase	Can precede, mostly after	Progressive course, blurry vision, photopsia, VA loss, VF defect, retinal thinning
Lung (SCCL, NSCCL, adenocarcinoma)	11% (47/441)	Enolase, p62, CAII	Can precede	Sudden onset, color vision loss, retinal thinning, vascular abnormalities
Colon	5% (21/441)	Aldolase, CAII, enolase, (arrestin, recoverin)	Can precede	Sudden onset, progressive course, blurry vision, central vision loss, color vision loss, cone-ffERG dysfunction, retinal thinning
Prostate	8% (35/441)	CAII, recoverin	Can precede	Progressive course, nyctalopia, VF defects, ERG dysfunction, attenuated vessels
Thyroid	4% (16/441)	Enolase, arrestin	At the time diagnosis or after	Photopsia/photophobia, peripheral vision loss, VA loss, rod-ffERG dysfunction, retinal thinning
Melanoma	18% (78/441)	Enolase, CAII, arrestin	After	Gradual loss, nyctalopia, VA loss, rod-ERG dysfunction
Lymphomas	4% (17/441)	Arrestin, Enolase, p62	After	VA loss, VF loss
Bladder	3% (12/441)	CAII, Enolase, GADPH	At the time diagnosis or after	Progressive course, VA loss, ERG dysfunction; color vison loss

VA = visual acuity, ERG = electroretinogram; VF = visual field